Antibacterial composition comprising salicylic acid and succinic acid

Abstract

One aspect provides an antibacterial composition comprising salicylic acid and succinic acid in a weight ratio of 1: 1 to 1.9. The composition exhibits an excellent antibacterial effect compared to a single component as a result of a synergistic effect between the two components, and particularly, exhibits an excellent antibacterial effect against acne-causing bacteria. In addition, when applied to acne-prone skin, the composition exhibits a prevention, reduction, or treatment effect on acne-related symptoms without side-effects.

Description

Antibacterial composition containing salicylic acid and succinic acid

[0001] It relates to an antibacterial composition containing salicylic acid and succinic acid.

[0002]

[0003] Acne is a common skin condition that occurs when pores become clogged with sebum and dead skin cells. While acne is most common in adolescence, it can also occur in adults, appearing on the face, neck, chest, and back. Acne can manifest as whiteheads, red, inflamed blisters, and deeper cysts. Its severity ranges from mild to severe, and in severe cases, it can lead to psychological stress in addition to skin problems.

[0004] Salicylic acid is a key ingredient used in acne products for its anti-inflammatory properties and ability to soften and remove dead skin cells that clog pores and cause acne. However, when applied in high concentrations to alleviate acne, it can cause side effects such as dryness, itchiness, and erythema.

[0005] Meanwhile, succinic acid is known to have almost no side effects such as dryness, itchiness, and erythema.

[0006] Accordingly, the inventors of the present invention intend to provide an antibacterial composition comprising salicylic acid and succinic acid, which exhibits significantly superior acne prevention, improvement, or treatment effects even when treated at a lower concentration than when using a single ingredient, while reducing the side effects of salicylic acid, and a patch comprising the same.

[0007]

[0008] One aspect is to provide an antibacterial composition comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0009] Another aspect provides a pharmaceutical composition for preventing or treating bacterial or fungal infectious skin diseases, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0010] Another aspect provides an antibacterial cosmetic composition comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0011] Another aspect provides an antibacterial skin external preparation comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0012] Another aspect is an antibacterial layer comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9; and

[0013] A patch having a multi-layer structure is provided, which is disposed on the first surface of the antibacterial layer and includes a coating layer comprising thermoplastic polyurethane (TPU).

[0014]

[0015] One aspect provides an antibacterial composition comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0016] Specifically, the antibacterial composition may contain salicylic acid and succinic acid in a weight ratio of 1: 1 to 1.9, 1: 1 to 1.7, 1: 1 to 1.5, 1: 1 to 1.3, 1: 1.3 to 1.9, 1: 1.3 to 1.7, 1: 1.3 to 1.5, 1: 1.5 to 1.9, 1: 1.5 to 1.7, or 1: 1.7 to 1.9.

[0017] When salicylic acid and succinic acid are included in the above antibacterial composition at a weight ratio of 1:1 to 1.9, a significantly superior antibacterial effect is exhibited through a synergistic effect compared to when only a single component is used, specifically, an antibacterial effect against acne-causing bacteria is exhibited, and when applied to skin with acne, acne symptoms are significantly reduced. On the other hand, when salicylic acid and succinic acid are included in the above antibacterial composition at a weight ratio of less than 1:1, the antibacterial effect is significantly reduced, and when applied to skin with acne, side effects such as itching and redness caused by salicylic acid increase, and when salicylic acid and succinic acid are included at a weight ratio of more than 1:1.9, the antibacterial effect is significantly reduced.

[0018] In one specific example, the salicylic acid may be included in an amount of 0.3 to 0.5 wt% relative to the total weight of the antibacterial composition. Specifically, the salicylic acid may be included in an amount of 0.3 to 0.5 wt%, 0.3 to 0.5 wt%, 0.3 to 0.45 wt%, 0.3 to 0.4 wt%, 0.3 to 0.35 wt%, 0.35 to 0.5 wt%, 0.35 to 0.45 wt%, 0.35 to 0.4 wt%, 0.4 to 0.5 wt%, 0.4 to 0.45 wt%, or 0.45 to 0.5 wt% relative to the total weight of the antibacterial composition.

[0019] When the salicylic acid is included in an amount of 0.3 to 0.5 wt% based on the total weight of the antibacterial composition, side effects such as itching and redness are minimized when the antibacterial composition is applied to the skin, and a remarkably excellent antibacterial effect, specifically, an antibacterial effect against acne-causing bacteria, is exhibited. On the other hand, when the salicylic acid is included in an amount of less than 0.3 wt% based on the total weight of the antibacterial composition, the antibacterial effect is remarkably low, and when it is included in an amount exceeding 0.5 wt%, side effects such as itching and redness are increased when the antibacterial composition is applied to the skin.

[0020] The above "salicylic acid" has a structure represented by the following chemical formula 1. It is a carboxylic acid corresponding to BHA (β-hydroxy acid). It softens dead skin cells, facilitating their removal, and helps remove sebum from pores. Therefore, it is used as an exfoliating agent in cosmetics:

[0021] [Chemical Formula 1]

[0022] .

[0023] The above "succinic acid" has a structure represented by the following chemical formula 2 and is a natural ingredient found in pumpkins, some berries, mushrooms, seaweed, and fermented foods. Succinic acid is known to exhibit anti-inflammatory and antioxidant properties and is therefore used as an additive in cosmetics:

[0024] [Chemical Formula 2]

[0025] .

[0026] The above “antibacterial” means inhibition of growth, growth or proliferation of all microorganisms (e.g., bacteria, fungi, etc.).

[0027] Specifically, the antibacterial agent is Corynebacterium striatum, Streptococcus pyogenes, Pseudomonas aeruginosa, Bacillus cereus, Micrococcus flavus, Campylobacter jejuni, Vibrio parahaemolyticus, Aspergillus niger, Candida albicans, Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Epidermophyton floccosum, It may inhibit the growth, growth or proliferation of one or more microorganisms selected from the group consisting of Cutibacterium acnes, Staphylococus aureus and Staphylococus epidermidis.

[0028] In one specific example, the antibacterial effect may be due to inhibition of growth, growth, or proliferation of acne-causing bacteria.

[0029] In one specific example, the acne-causing bacteria may be at least one selected from the group consisting of Cutibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis. Specifically, the acne-causing bacteria may be all of Cutibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis.

[0030] In one specific example, the antibacterial composition may alleviate acne symptoms.

[0031] In one specific example, the acne symptom may be at least one selected from the group consisting of open comedones, closed comedones, papules, pustules, nodules, erythema, pseudocysts, and pustules. Specifically, the acne symptom may be all of open comedones, closed comedones, papules, pustules, nodules, erythema, pseudocysts, and pustules.

[0032] In one experimental example, the antibacterial activity of a composition containing salicylic acid and succinic acid against Cutibacterium acnes, a known acne-causing bacterium, was confirmed. As a result, when Examples 1 to 3 containing salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9 were treated, a remarkably excellent antibacterial effect was observed, and in particular, in the case of Example 1, it was confirmed that a remarkably excellent antibacterial effect was observed compared to when Comparative Examples 1 to 3 using a single component and Comparative Examples 4 to 6 in which the ratio of the components was changed to less than 1:1 or greater than 1:1.9 were treated (see Experimental Example 1).

[0033] The antibacterial composition according to one aspect exhibits remarkably excellent antibacterial effects, specifically, excellent antibacterial effects against acne-causing bacteria. Furthermore, when applied to acne-affected skin, the composition can alleviate acne-related symptoms without side effects, making the antibacterial composition according to one aspect effective in preventing, alleviating, or treating acne.

[0034]

[0035] Another aspect provides a pharmaceutical composition for preventing or treating bacterial or fungal skin infections, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0036] The above “salicylic acid”, “succinic acid”, “acne”, etc. may be within the aforementioned range.

[0037] Specifically, the pharmaceutical composition may contain salicylic acid and succinic acid in a weight ratio of 1: 1 to 1.9, 1: 1 to 1.7, 1: 1 to 1.5, 1: 1 to 1.3, 1: 1.3 to 1.9, 1: 1.3 to 1.7, 1: 1.3 to 1.5, 1: 1.5 to 1.9, 1: 1.5 to 1.7 or 1: 1.7 to 1.9.

[0038] When salicylic acid and succinic acid are included in the pharmaceutical composition at a weight ratio of 1:1 to 1.9, a significantly superior antibacterial effect is exhibited through a synergistic effect compared to when only a single ingredient is used, specifically, an antibacterial effect against acne-causing bacteria is exhibited, and when applied to skin with acne, acne symptoms are significantly reduced. On the other hand, when salicylic acid and succinic acid are included in the pharmaceutical composition at a weight ratio of less than 1:1, the antibacterial effect is significantly reduced, and when applied to skin with acne, side effects such as itching and redness caused by salicylic acid increase, and when salicylic acid and succinic acid are included at a weight ratio of more than 1:1.9, the antibacterial effect is significantly reduced.

[0039] In one specific example, the salicylic acid may be included in an amount of 0.3 to 0.5 wt% relative to the total weight of the pharmaceutical composition. Specifically, the salicylic acid may be included in an amount of 0.3 to 0.5 wt%, 0.3 to 0.5 wt%, 0.3 to 0.45 wt%, 0.3 to 0.4 wt%, 0.3 to 0.35 wt%, 0.35 to 0.5 wt%, 0.35 to 0.45 wt%, 0.35 to 0.4 wt%, 0.4 to 0.5 wt%, 0.4 to 0.45 wt%, or 0.45 to 0.5 wt% relative to the total weight of the pharmaceutical composition.

[0040] When the salicylic acid is included in an amount of 0.3 to 0.5 wt% based on the total weight of the pharmaceutical composition, side effects such as itching and redness are minimized when the pharmaceutical composition is applied to the skin, and a remarkably excellent antibacterial effect, specifically, an antibacterial effect against acne-causing bacteria, is exhibited. On the other hand, when the salicylic acid is included in an amount of less than 0.3 wt% based on the total weight of the pharmaceutical composition, the antibacterial effect is remarkably low, and when it is included in an amount exceeding 0.5 wt%, side effects such as itching and redness are increased when the pharmaceutical composition is applied to the skin.

[0041] The term "bacterial or fungal skin disease" above refers to a skin disease caused by bacterial or fungal infection. For example, bacteria that cause skin diseases through infection include Staphylococcus, Streptococcus, and Cutibacterium, while fungi include Trichophyton, Microsporum, and Epidermophyton.

[0042] The above term "prevention" may mean any act of inhibiting or delaying the occurrence of a bacterial or fungal infectious skin disease in an individual by administering a pharmaceutical composition according to one aspect.

[0043] The term "treatment" above may mean any action that improves or beneficially changes the symptoms of a bacterial or fungal infectious skin disease in an individual by administering a pharmaceutical composition according to one aspect.

[0044] Additionally, the pharmaceutical composition may be provided as a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers, excipients and / or diluents.

[0045] Specifically, the carrier may be, for example, a colloidal suspension, a powder, a saline solution, a lipid, a liposome, microspheres, or nano-spheres. These may be complexed or associated with a carrier vehicle and may be transported in vivo using carrier systems known in the art, such as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation agents, polysaccharides, polyamino acids, dendrimers, saponins, adsorption enhancing substances, or fatty acids.

[0046] When the above pharmaceutical composition is formulated, it can be prepared using diluents or excipients such as lubricants, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants that are commonly used. Solid preparations for oral administration may include tablets, pills, powders, granules, capsules, oral dissolving films, patches, etc., and such solid preparations can be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., with the above composition. In addition to simple excipients, lubricants such as magnesium stearate and talc can also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. Preparations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and patches. Non-aqueous solvents and suspending agents may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases may include witepsol, macrogol, tween 61, cacao butter, laurin butter, and glycerogelatin. When manufacturing in the form of eye drops, known diluents or excipients may be used.

[0047] The above pharmaceutical composition is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment. The effective dosage level may be determined based on the type and severity of the patient's disease, the activity and sensitivity of the drug, the time of administration, the route of administration and excretion rate, the duration of treatment, concomitant medications, and other factors well known in the medical field. The above administration may be administered once a day or in several divided doses. For example, it may be administered every other day or once a week.

[0048] The term "administration" above refers to introducing a given substance into an individual through an appropriate method, and "individual" refers to any living organism, including rats, mice, pigs, horses, cows, and livestock, including humans, that may have a scalp disease. A specific example may be a mammal, including humans.

[0049] The above pharmaceutical composition may be administered orally or parenterally, and when administered parenterally, the method of administration may be selected from external application to the skin, application of a patch, or injection into the intraperitoneal cavity, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intraarterial injection, intramedullary injection, intracardiac injection, intrathecal injection, percutaneous injection, intranasal injection, intraenteric injection, local injection, sublingual injection, rectal injection, or intrathoracic injection.

[0050] In one aspect, the pharmaceutical composition may further comprise another agent for treating bacterial or fungal skin infections.

[0051] The above other bacterial or fungal infectious skin disease treatment agent may be included in the pharmaceutical composition in the minimum amount that can achieve maximum effect without side effects, which can be easily determined by a person skilled in the art.

[0052] Additionally, in one aspect, the pharmaceutical composition may be administered alone or in combination with other known bacterial or fungal infectious skin disease treatment agents. That is, the pharmaceutical composition may be administered in combination with other bacterial or fungal infectious skin disease treatment agents, and may be administered simultaneously, separately, or sequentially, and may be administered singly or in multiple doses.

[0053] When the above-mentioned other bacterial or fungal infectious skin disease treatment agent is administered in combination with the above-mentioned pharmaceutical composition, it may be administered in an amount or ratio that can achieve the maximum effect without side effects, which can be easily determined by a person skilled in the art.

[0054] The above other bacterial or fungal infectious skin disease treatment agent may be a conventionally known bacterial or fungal infectious skin disease treatment agent or a newly developed bacterial or fungal infectious skin disease treatment agent.

[0055] In one specific example, the bacterial or fungal infectious skin disease may be at least one selected from the group consisting of acne, folliculitis, boils, psoriasis, erythema, pustular eczema, impetigo, lymphadenitis, cellulitis, tinea, and candidiasis. Specifically, in one specific example, the bacterial or fungal infectious skin disease may be acne, folliculitis, boils, psoriasis, erythema, pustular eczema, impetigo, lymphadenitis, cellulitis, tinea, and candidiasis. More specifically, the bacterial or fungal infectious skin disease may be acne.

[0056] In one specific example, the pharmaceutical composition may inhibit the growth, development, or proliferation of bacteria or fungi. Specifically, the bacteria or fungi may be acne-causing bacteria.

[0057] In one specific example, the bacteria or fungi are Corynebacterium striatum, Streptococcus pyogenes, Pseudomonas aeruginosa, Bacillus cereus, Micrococcus flavus, Campylobacter jejuni, Vibrio parahaemolyticus, Aspergillus niger, Candida albicans, Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Epidermophyton It may be at least one selected from the group consisting of Epidermophyton floccosum, Cutibacterium acnes, Staphylococus aureus, and Staphylococus epidermidis.

[0058] In one specific example, the bacteria or fungi may be acne-causing bacteria. Specifically, the acne-causing bacteria may be at least one selected from the group consisting of Cutibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis, and more specifically, may be all of Cutibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis.

[0059] In one specific example, the pharmaceutical composition may prevent or treat acne symptoms.

[0060] In one specific example, the acne symptom may be at least one selected from the group consisting of open comedones, closed comedones, papules, pustules, nodules, erythema, pseudocysts, and pustules. Specifically, the acne symptom may be all of open comedones, closed comedones, papules, pustules, nodules, erythema, pseudocysts, and pustules.

[0061] The pharmaceutical composition according to one aspect exhibits remarkably excellent antibacterial effects, specifically, excellent antibacterial effects against acne-causing bacteria. Furthermore, when applied to acne-affected skin, the pharmaceutical composition can alleviate acne-related symptoms without side effects, making it effective in preventing, alleviating, or treating acne.

[0062]

[0063] Another aspect provides an antibacterial cosmetic composition comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0064] The above “salicylic acid”, “succinic acid”, “acne”, “antibacterial”, etc. may be within the above-mentioned range.

[0065] Specifically, the cosmetic composition may contain salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, 1:1 to 1.7, 1:1 to 1.5, 1:1 to 1.3, 1:1.3 to 1.9, 1:1.3 to 1.7, 1:1.3 to 1.5, 1:1.5 to 1.9, 1:1.5 to 1.7 or 1:1.7 to 1.9.

[0066] When salicylic acid and succinic acid are included in the above cosmetic composition at a weight ratio of 1:1 to 1.9, a significantly superior antibacterial effect, specifically an antibacterial effect against acne-causing bacteria, is exhibited through a synergistic effect compared to when only a single ingredient is used, and when applied to skin with acne, acne symptoms are significantly reduced. On the other hand, when salicylic acid and succinic acid are included in the above cosmetic composition at a weight ratio of less than 1:1, the antibacterial effect is significantly reduced, and when applied to skin with acne, side effects such as itching and redness caused by salicylic acid increase, and when salicylic acid and succinic acid are included at a weight ratio of more than 1:1.9, the antibacterial effect is significantly reduced.

[0067] In one specific example, the salicylic acid may be included in an amount of 0.3 to 0.5 wt% relative to the total weight of the cosmetic composition. Specifically, the salicylic acid may be included in an amount of 0.3 to 0.5 wt%, 0.3 to 0.5 wt%, 0.3 to 0.45 wt%, 0.3 to 0.4 wt%, 0.3 to 0.35 wt%, 0.35 to 0.5 wt%, 0.35 to 0.45 wt%, 0.35 to 0.4 wt%, 0.4 to 0.5 wt%, 0.4 to 0.45 wt%, or 0.45 to 0.5 wt% relative to the total weight of the cosmetic composition.

[0068] When the salicylic acid is included in an amount of 0.3 to 0.5 wt% based on the total weight of the cosmetic composition, side effects such as itching and redness are minimized when the cosmetic composition is applied to the skin, and a remarkably excellent antibacterial effect, specifically, an antibacterial effect against acne-causing bacteria, is exhibited. On the other hand, when the salicylic acid is included in an amount of less than 0.3 wt% based on the total weight of the cosmetic composition, the antibacterial effect is remarkably low, and when it is included in an amount exceeding 0.5 wt%, side effects such as itching and redness are increased when the cosmetic composition is applied to the skin.

[0069] In one specific example, the antibacterial effect may be due to inhibition of growth, growth, or proliferation of acne-causing bacteria.

[0070] In one specific example, the cosmetic composition may alleviate acne symptoms.

[0071] The above cosmetic composition can be manufactured into any formulation commonly manufactured in the technical field to which the present invention pertains. For example, it can be formulated into a softening toner, a nourishing toner, an emulsion, a lotion, a cream, a paste, a gel, a solution, a suspension, an oil, a wax, a pack, a powder, a foundation, a spray, a surfactant-containing cleanser, a patch, etc. More specifically, it can be manufactured into a formulation of a tonic, a skin lotion, a skin softener, a skin toner, a nourishing cream, a limb cream, a milk lotion, a powder, an essence, an eye cream, a sun lotion, a sunscreen, a makeup primer, a makeup base, a BB cream, a powder foundation, an emulsion foundation, a cleansing cream, a cleansing foam, a cleansing water, a soap, a pack, a stick product, a balm-type product, a patch, a spray, or a powder.

[0072] The above cosmetic composition may further comprise any conventional cosmetic ingredient selected from additional ingredients commonly used in cosmetics, such as thickeners, dispersants, fragrances, fillers, preservatives, antiseptics, neutralizers, sweeteners, vitamins, free-radical scavengers, metal ion sequestrants, functional ingredients, and mixtures thereof. A person skilled in the art can select any additional ingredient and / or its amount such that the advantageous properties of the composition according to the present disclosure are not or are substantially not adversely affected by the anticipated addition.

[0073] When the above cosmetic composition is a surfactant-containing cleansing formulation, it may further include, as a carrier component, an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyl taurate, a sarcosinate, a fatty acid amide ether sulfate, an alkylamidobetaine, an aliphatic alcohol, a fatty acid glyceride, a fatty acid diethanolamide, a vegetable oil, a linolenic derivative, or an ethoxylated glycerol fatty acid ester.

[0074] If the above cosmetic composition is in the form of a cream or gel, it may further include animal oil, vegetable oil, wax, paraffin, starch, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide as a carrier component.

[0075] When the above cosmetic composition is in the form of a solution or emulsion, it may further include a solvent, solvating agent or emulsifying agent, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, propylene glycol, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.

[0076] If the above cosmetic composition is in the form of a suspension formulation, it may further include a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth as a carrier component.

[0077] If the above cosmetic composition is in a powder or spray form, it may further include lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder as a carrier component, and particularly if it is in a spray form, it may further include a propellant such as chlorofluorohydrocarbon, propane / butane or dimethyl ether.

[0078] The above cosmetic composition may be applied alone or in combination, or may be applied in combination with other cosmetic compositions. Furthermore, the above cosmetic composition may be used according to conventional methods, and the frequency of application may vary depending on the user's skin condition or preference.

[0079] The cosmetic composition according to one aspect exhibits remarkably excellent antibacterial effects, specifically, excellent antibacterial effects against acne-causing bacteria. Furthermore, when applied to acne-affected skin, the cosmetic composition can alleviate acne-related symptoms without side effects, making it effective in preventing, alleviating, or treating acne.

[0080]

[0081] Another aspect provides an antibacterial skin external preparation comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9.

[0082] The above “salicylic acid”, “succinic acid”, “acne”, “antibacterial”, etc. may be within the above-mentioned range.

[0083] Specifically, the skin external preparation may contain salicylic acid and succinic acid in a weight ratio of 1: 1 to 1.9, 1: 1 to 1.7, 1: 1 to 1.5, 1: 1 to 1.3, 1: 1.3 to 1.9, 1: 1.3 to 1.7, 1: 1.3 to 1.5, 1: 1.5 to 1.9, 1: 1.5 to 1.7, or 1: 1.7 to 1.9.

[0084] When salicylic acid and succinic acid are included in the above skin external preparation at a weight ratio of 1:1 to 1.9, a significantly superior antibacterial effect is exhibited through a synergistic effect compared to when only a single ingredient is used, specifically, an antibacterial effect against acne-causing bacteria is exhibited, and when applied to skin with acne, acne symptoms are significantly reduced. On the other hand, when salicylic acid and succinic acid are included in the above skin external preparation at a weight ratio of less than 1:1, the antibacterial effect is significantly reduced, and when applied to skin with acne, side effects such as itching and redness caused by salicylic acid increase, and when salicylic acid and succinic acid are included at a weight ratio of more than 1:1.9, the antibacterial effect is significantly reduced.

[0085] In one specific example, the salicylic acid may be included in an amount of 0.3 to 0.5 wt% relative to the total weight of the external preparation for skin. Specifically, the salicylic acid may be included in an amount of 0.3 to 0.5 wt%, 0.3 to 0.5 wt%, 0.3 to 0.45 wt%, 0.3 to 0.4 wt%, 0.3 to 0.35 wt%, 0.35 to 0.5 wt%, 0.35 to 0.45 wt%, 0.35 to 0.4 wt%, 0.4 to 0.5 wt%, 0.4 to 0.45 wt%, or 0.45 to 0.5 wt% relative to the total weight of the external preparation for skin.

[0086] When the salicylic acid is included in an amount of 0.3 to 0.5 wt% based on the total weight of the external preparation for skin, side effects such as itching and redness are minimized when the external preparation for skin is applied to the skin, and a remarkably excellent antibacterial effect, specifically, an antibacterial effect against acne-causing bacteria, is exhibited. On the other hand, when the salicylic acid is included in an amount of less than 0.3 wt% based on the total weight of the external preparation for skin, the antibacterial effect is remarkably low, and when it is included in an amount exceeding 0.5 wt%, side effects such as itching and redness are increased when the external preparation for skin is applied to the skin.

[0087] In one specific example, the antibacterial effect may be due to inhibition of growth, growth, or proliferation of acne-causing bacteria.

[0088] In one specific example, the skin external preparation may alleviate acne symptoms.

[0089] The above-mentioned external skin preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, drug-containing bandage, lotion, shampoo, rinse, treatment, tonic, hair pack, or a combination thereof. The above-mentioned external skin preparation may be appropriately mixed with ingredients commonly used in external skin preparations such as cosmetics or medicines, such as aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or a combination thereof, as needed. The above skin external preparation may also appropriately contain metal sequestrants such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; caffeine, tannin, bellapamil, licorice extract, glabridin, hot water extract of the fruit of Kalin; various herbal medicines; drugs such as tocopherol acetate, glycyrrhizic acid, tranexamic acid and derivatives or salts thereof; vitamin C, magnesium ascorbic acid phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, and trehalose; and the like.

[0090] Topical skin preparations, depending on the type of skin, exhibit remarkably excellent antibacterial effects, particularly against acne-causing bacteria. Furthermore, when applied to acne-prone skin, these topical preparations can alleviate acne-related symptoms without side effects, making them effective in preventing, alleviating, or treating acne.

[0091]

[0092] Another aspect is an antibacterial layer comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9; and

[0093] A patch having a multi-layer structure is provided, which is disposed on the first surface of the antibacterial layer and includes a coating layer comprising thermoplastic polyurethane (TPU).

[0094] The above “salicylic acid”, “succinic acid”, “acne”, “antibacterial”, etc. may be within the above-mentioned range.

[0095] In one specific example, the coating layer may be made of thermoplastic polyurethane.

[0096] Specifically, the patch may contain salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9, 1:1 to 1.7, 1:1 to 1.5, 1:1 to 1.3, 1:1.3 to 1.9, 1:1.3 to 1.7, 1:1.3 to 1.5, 1:1.5 to 1.9, 1:1.5 to 1.7 or 1:1.7 to 1.9.

[0097] When salicylic acid and succinic acid are included in the patch at a weight ratio of 1:1 to 1.9, a significantly superior antibacterial effect is exhibited through a synergistic effect compared to when only a single ingredient is used, specifically, an antibacterial effect against acne-causing bacteria is exhibited, and when applied to skin with acne, acne symptoms are significantly reduced. On the other hand, when salicylic acid and succinic acid are included in the patch at a weight ratio of less than 1:1, the antibacterial effect is significantly reduced, and when applied to skin with acne, side effects such as itching and redness caused by salicylic acid increase, and when salicylic acid and succinic acid are included at a weight ratio of more than 1:1.9, the antibacterial effect is significantly reduced.

[0098] In one specific example, the salicylic acid may be included in an amount of 0.3 to 0.5 wt% relative to the total weight of the antibacterial layer. Specifically, the salicylic acid may be included in an amount of 0.3 to 0.5 wt%, 0.3 to 0.5 wt%, 0.3 to 0.45 wt%, 0.3 to 0.4 wt%, 0.3 to 0.35 wt%, 0.35 to 0.5 wt%, 0.35 to 0.45 wt%, 0.35 to 0.4 wt%, 0.4 to 0.5 wt%, 0.4 to 0.45 wt%, or 0.45 to 0.5 wt% relative to the total weight of the antibacterial layer.

[0099] When the salicylic acid is included in an amount of 0.3 to 0.5 wt% based on the total weight of the antibacterial layer, side effects such as itching and redness are minimized when the patch is applied to the skin, and a remarkably excellent antibacterial effect, specifically, an antibacterial effect against acne-causing bacteria, is exhibited. On the other hand, when the salicylic acid is included in an amount of less than 0.3 wt% based on the total weight of the antibacterial layer, the antibacterial effect is remarkably low, and when it is included in an amount exceeding 0.5 wt%, side effects such as itching and redness are increased when the patch is applied to the skin.

[0100] In one specific example, the antibacterial layer may have an activity of inhibiting the growth, growth, or proliferation of acne-causing bacteria.

[0101] In one specific example, the antibacterial layer may be a hydrogel.

[0102] The above "hydrogel" is a material having a three-dimensional network structure formed through cross-linking of hydrophilic polymers. It can contain a large amount of moisture within the three-dimensional structure, exhibiting physicochemical properties that correspond to intermediate states between liquid and solid.

[0103] In one specific example, the hydrogel may be a cross-linked hydrophilic polymer.

[0104] The aforementioned "cross-linking" is a chemical reaction that connects polymer chains through chemical bonds (covalent bonds, non-covalent bonds, etc.). For example, when cross-linking is formed between hydrophilic polymers, the polymer chains connect like a net, forming a three-dimensional network structure.

[0105] In one specific example, the hydrophilic polymer may be at least one selected from the group consisting of carboxymethyl cellulose, gelatin, collagen, pectin, ethyl cellulose, methylcellulose, polyether, hydroxypropylmethylcellulose, carmellose sodium, xanthan gum, and alginate. Specifically, the hydrophilic polymer may be carboxymethyl cellulose.

[0106] In one specific example, the antibacterial layer may further include an adhesive.

[0107] In one specific example, the adhesive is a hydrogenated styrene / butadiene copolymer, a hydrogenated poly(C6-20 olefin), mineral oil, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, polyethylene glycol (PEG), poloxamer 407, rosin, glycol rosinate, glyceryl rosinate, pentaerythritol rosinate, hydrogenated It may be at least one selected from the group consisting of hydrogenated rosinate, polyvinylpyrrolidone, and polyvinylpyrrolidone / vinyl acetate copolymer.

[0108] Specifically, the adhesive may be at least one selected from the group consisting of a hydrogenated styrene / butadiene copolymer, a hydrogenated poly(C6-20 olefin), mineral oil, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, polyethylene glycol (PEG), and poloxamer 407. More specifically, the adhesive may be a hydrogenated styrene / butadiene copolymer, a hydrogenated poly(C6-20 olefin), mineral oil, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, polyethylene glycol (PEG), and poloxamer 407.

[0109] The above "antibacterial layer" contains salicylic acid and succinic acid, and when attached to the skin, releases the salicylic acid and succinic acid to inhibit the growth, development, or proliferation of microorganisms present on the skin, specifically, acne-causing bacteria. Specifically, the antibacterial layer has a surface that is attached to the skin as the second surface, and a first surface that faces the second surface of the antibacterial layer, to which a coating layer is attached.

[0110] In addition, the antibacterial layer further comprises a hydrocolloid component, which absorbs exudates generated by microbial infections, wounds, etc., and creates a moist environment to promote skin regeneration, protect wounds, and prevent infection. Furthermore, the antibacterial layer additionally comprises an adhesive component, which allows the patch to adhere to the skin without moving.

[0111] The above "coating layer" is a layer present on the first side of the antibacterial layer, and seals the first side of the antibacterial layer, which is the side facing outward and not the skin, so that the salicylic acid and succinic acid present in the antibacterial layer can be released only to the skin through the second side, thereby protecting the acne area. In addition, the TPU included in the coating layer has the advantage of being thin and not leaving a mark even when attached to the skin.

[0112] In one embodiment, the patch is disposed on the second side of the antibacterial layer and may further include a release film layer comprising polyethylene terephthalate (PET). Specifically, the patch may further include a release film layer made of polyethylene terephthalate (PET).

[0113] The above "release film layer" is a layer placed on the second side of the antibacterial layer, which is the side that is attached to the skin when the patch is actually used on the skin, and serves to protect the salicylic acid and succinic acid of the antibacterial layer from being released to the outside until immediately before use, and protects the adhesive surface of the antibacterial layer from the outside, thereby enabling hygienic use and maintaining adhesive strength. In addition, it serves to enable the patch to be easily removed immediately before use.

[0114] In one specific example, the thickness of the patch may be 0.225 to 0.275 mm. Specifically, the thickness of the patch may be 0.225 to 0.275 mm, 0.225 to 0.255 mm, 0.225 to 0.245 mm, 0.225 to 0.235 mm, 0.235 to 0.275 mm, 0.235 to 0.255 mm, 0.235 to 0.245 mm, 0.245 to 0.275 mm, 0.245 to 0.255 mm, or 0.255 to 0.275 mm.

[0115] Specifically, the thickness of the above patch refers to the thickness of the patch composed of a coating layer and an antibacterial layer.

[0116] When the thickness of the above patch is 0.225 to 0.275 mm, when the patch is attached to the skin, it is attached thinly so that the position where the patch is attached is not noticeable, and some parts do not fall off even on curved skin surfaces and can be attached well. On the other hand, when the thickness of the above patch is less than 0.225 mm, it is too thin and can be easily torn, and when it exceeds 0.275 mm, the position where the patch is attached is noticeable and the thickness is thick so that it can easily fall off on curved skin surfaces.

[0117] In one specific example, the tensile strength of the patch may be 1400 to 1700 gf / 12 mm. Specifically, the tensile strength of the patch may be 1400 to 1700 gf / 12 mm, 1400 to 1600 gf / 12 mm, 1400 to 1500 gf / 12 mm, 1400 to 1450 gf / 12 mm, 1450 to 1700 gf / 12 mm, 1450 to 1600 gf / 12 mm, 1450 to 1500 gf / 12 mm, 1500 to 1700 gf / 12 mm, 1500 to 1600 gf / 12 mm, or 1600 to 1700 gf / 12 mm.

[0118] The term "tensile strength" above refers to the maximum force that the patch can withstand without breaking when subjected to an elongating force. When the tensile strength of the patch is 1400 to 1700 gf / 12 mm, the patch exhibits excellent durability without tearing when peeled off from the release film layer for use. On the other hand, when the tensile strength of the patch is less than 1400 gf / 12 mm, the patch may be easily torn, and when it exceeds 1700 gf / 12 mm, it may be too hard and easily broken.

[0119] In one specific example, the adhesive force of the patch may be 500 to 600 gf / 12 mm. Specifically, the adhesive force of the patch may be 500 to 600 gf / 12 mm, 500 to 570 gf / 12 mm, 500 to 550 gf / 12 mm, 500 to 530 gf / 12 mm, 530 to 600 gf / 12 mm, 530 to 570 gf / 12 mm, 530 to 550 gf / 12 mm, 550 to 600 gf / 12 mm, 550 to 570 gf / 12 mm, or 570 to 600 gf / 12 mm.

[0120] The term "adhesion" above refers to the ability of the patch to remain attached to the skin without coming off when a certain force is applied to the patch when it is attached to the skin. When the adhesive strength of the patch is 500 to 600 gf / 12 mm, the patch does not come off easily over time and remains stably attached on all sides even on curved surfaces of the skin. On the other hand, when the adhesive strength of the patch is less than 500 gf / 12 mm, the patch does not adhere to the skin and comes off easily, and when it exceeds 600 gf / 12 mm, the patch does not come off from the skin and the skin may be damaged when the patch is removed.

[0121] In one specific example, the absorption rate of the patch is 550 to 650% (24 hrs, g / cm 2 ) may be. Specifically, the absorption rate of the patch is 550 to 650% (24 hrs, g / cm 2 ), 550 to 630% (24 hrs, g / cm 2 ), 550 to 610% (24 hrs, g / cm 2 ), 550 to 580% (24 hrs, g / cm 2 ), 580 to 650% (24 hrs, g / cm 2 ), 580 to 630% (24 hrs, g / cm 2 ), 580 to 610% (24 hrs, g / cm 2 ), 610 to 650% (24 hrs, g / cm 2 ), 610 to 630% (24 hrs, g / cm 2 ) or 630 to 650% (24 hrs, g / cm 2 ) may be.

[0122] The term "absorption rate" refers to the ability of a patch to absorb and retain moisture. For example, when a patch is applied to a wound, it refers to the ability to retain exudates (plasma proteins, moisture, platelets, white blood cells, enzymes, etc.) generated from the wound.

[0123] The absorption rate of the above patch is 550 to 650% (24 hrs, g / cm 2 ) absorbs exudates from the skin to create a moist environment and helps heal wounds caused by acne bacteria. Meanwhile, the absorption rate of the patch is 550% (24 hrs, g / cm 2 ) is less than 650% (24 hrs, g / cm), the patch cannot absorb the exudate from the skin wound and leaks out. 2 ) If it exceeds, the surrounding skin may become weak or damaged due to the excessively moist environment created.

[0124] In one experimental example, the physical properties of the above patch were evaluated, and the measurement results were as follows: thickness 0.230 mm, tensile strength 1496.90 gf / 12 mm, adhesive strength 543.00 gf / 12 mm, and absorption rate 615.00% (24 hrs, g / cm 2 ) was confirmed to have the characteristics of being thin enough to not leave a mark on the attachment location, being able to stably attach to the skin without tearing, and being able to absorb exudates generated from the wound to create a moist environment (see Experimental Example 2).

[0125] The patch, which is designed for daily use, exhibits remarkably excellent antibacterial effects, specifically against acne-causing bacteria. Furthermore, when applied to acne-prone skin, the patch can alleviate acne-related symptoms without side effects, making it effective in preventing, alleviating, or treating acne.

[0126]

[0127] An antibacterial composition containing salicylic acid and succinic acid exhibits superior antibacterial effects compared to single-ingredient formulations due to the synergistic effect between the two ingredients. In particular, it exhibits excellent antibacterial effects against acne-causing bacteria. Furthermore, when applied to acne-prone skin, the composition exhibits preventative, alleviative, or therapeutic effects on acne-related symptoms without adverse side effects.

[0128]

[0129] Figure 1 is a diagram showing the composition of each layer of an acne patch made of multiple layers.

[0130] Figure 2 is a diagram showing the results of measuring the antibacterial effect after treating Cutibacterium acnes with the positive control (ampicillin) and each of Examples 1 to 3.

[0131] Figure 3 is a diagram showing the results of measuring the antibacterial effect after treating Cutibacterium acnes with Comparative Examples 1 to 6.

[0132] Figure 4 is a drawing showing a photograph of an actually manufactured patch of the present invention.

[0133] Figure 5 is a photograph showing a patch of the present invention actually manufactured and attached to the skin.

[0134]

[0135] The present invention will be described in more detail below through examples. However, these examples are intended to exemplify the present invention and the scope of the present invention is not limited to these examples.

[0136]

[0137] <Manufacturing Example 1> Preparation of a composition containing salicylic acid and succinic acid

[0138] A composition containing salicylic acid and succinic acid was prepared by mixing powders with the composition shown in Table 1 below.

[0139] Comparative Example 1 Comparative Example 2 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Example 1 Example 2 Example 3 Salicylic acid (%) 240 0.30.50.55 0.40.40.35 Succinic acid (%) 0 0.40.60.40.35 0.50.55 0.55

[0140]

[0141] <Manufacturing Example 2> Manufacturing of an acne patch containing salicylic acid and succinic acid

[0142] As shown in Fig. 1, an acne patch composed of three layers was manufactured as follows.

[0143] The layers that make up a patch are as follows:

[0144] - Coating layer: Includes TPU

[0145] - Antibacterial layer: Contains antibacterial ingredients, adhesive, and hydrocolloid ingredients.

[0146] - Release film layer: Contains PET.

[0147] Specifically, a mixture of adhesive components, hydrogenated styrene / butadiene copolymer, hydrogenated poly(C6-20 olefin), mineral oil, and pentaerythrityl tetra-di-t-butylhydroxyhydrocinnamate, with the composition shown in Table 2 below, was stirred at 130 to 160° C. at 5 to 10 rpm for 45 minutes to completely dissolve the mixture. Then, cellulose gum was added to the above mixture solution and stirred at 5 to 10 rpm at 130 to 160°C for 3 hours to completely disperse all components, and then salicylic acid and succinic acid were added and stirred at 5 to 10 rpm at 130 to 160°C for 60 minutes to prepare a solution for an antibacterial layer film.

[0148] Next, the solution for manufacturing the antibacterial layer was stirred under vacuum at 110°C and 20 rpm for 30 minutes, and then stirred at 5 rpm for 100 minutes to perform a degassing process of the solution.

[0149] After the defoaming process, the defoamed solution was washed at 135°C, transferred to a tank, stored at 140±10°C, and then coated on a TPU film as a coating layer, and then manufactured by stamping after coating. In the case of a PET film as a release film layer, it can be added to protect the adhesive surface of the antibacterial layer during commercialization.

[0150] Role Ingredient Weight (%) AdhesiveHydrogenated Styrene / Butadiene Copolymer (Polystyrene-block-poly(ethylene-ran-butylene)-block-polystyrene)*CAS No. 66070-58-470.1Hydrogenated Poly (C6-20 Olefin)(poly(methylstyrene-co-indene))*CAS No. 69430-35-9Mineral Oil (White mineral oil; Petroleum; Paraffinum Liquidum)*CAS No. 8042-47-5Pentaerythrityl Tetra-di-t-butyl Hydroxyhydrocinnamate (pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate))*CAS No. 6683-19-8PEG-12 (Poly(ethylene glycol))*CAS No. 25322-68-3Poloxamer 407 (Pluronic F-127)*CAS No. 9003-11-06 Hydrocolloid Cellulose Gum (Carboxymethylcellulose, Sodium Salt)*CAS No. 9004-32-429.1 Active ingredient Salicylic acid*CAS No. 69-72-70.4Succinic acid*CAS No. 110-15-60.4

[0151]

[0152] <Experimental Example 1> Measurement of antibacterial effect (Paper disc method)

[0153] In order to confirm the acne prevention, improvement or treatment effect of Examples 1 to 3 and Comparative Examples 1 to 6 manufactured in Manufacturing Example 1 above, the antibacterial effect against Cutibacterium acnes, an acne bacterium, was evaluated.

[0154] Specifically, 100 μl of each of Examples 1 to 3 and Comparative Examples 1 to 6 was soaked on a sterilized paper disc, dried for 30 minutes, and then placed on a medium. Then, C. acnes (inoculation amount: 1Х10 4 ~ 1Х10 5 ) was poured onto the inoculated medium, allowed to solidify, and cultured in an incubator at 35±2.5°C for 24 hours. Afterwards, the size of the growth inhibition zone formed around the paper disk was measured. As a positive control, ampicillin, known as an antibiotic, was used, and in the case of ampicillin, a growth inhibition zone of 14.7 mm was observed.

[0155] As shown in FIGS. 2, 3 and Table 3 below, Examples 1 to 3 all exhibited growth inhibition zones of 11.6 mm or more, demonstrating excellent anti-acne bacteria activity. In the case of Example 1, it was confirmed that it exhibited growth inhibition zones similar to those of ampicillin, which was used as a positive control, and had a remarkably excellent anti-acne bacteria effect.

[0156] On the other hand, in the case of Comparative Examples 1 to 3, which are single components, the size of the growth inhibition zone was smaller than that of Example 1 even though the substance was treated at a high concentration of 2% or 4%, which is about 2.2 times or more than that of Examples 1 to 3, and the size was similar to that of Examples 2 and 3. In addition, when the ratio of salicylic acid and succinic acid was 1:2 or more (Comparative Example 4) or 1.25 to 1.57:1 (Comparative Examples 5 and 6), the growth inhibition zone was 10 to 10.6 mm, showing a low anti-acne effect.

[0157] Through the above results, it was confirmed that when salicylic acid and succinic acid were mixed in the ratios of Examples 1 to 3, a significantly superior anti-acne effect was exhibited through a synergistic effect.

[0158] Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Comparative Example 6 Example 1 Example 2 Example 3 Growth inhibition zone (mm) 10.1 12.2 11.4 10 10.3 10.6 14 11.6 11.6

[0159]

[0160] <Experimental Example 2> Measurement of physical properties (thickness, tensile strength, adhesiveness, and absorption rate) of acne patches

[0161] According to the results confirmed in the above Experimental Example 1, when salicylic acid and succinic acid are mixed, specifically, when the ratio of succinic acid is higher than that of salicylic acid and when salicylic acid and succinic acid are mixed in a ratio of less than 1:2, it was confirmed that a remarkably excellent acne prevention, improvement or treatment effect is exhibited through a synergistic effect.

[0162] Accordingly, a patch containing a mixture of salicylic acid and succinic acid was manufactured according to Manufacturing Example 2, and it was confirmed whether it exhibited properties (thickness, tensile strength, adhesiveness, and absorption rate) suitable for application to actual skin.

[0163] Specifically, the thickness was measured using a caliper (Mitudoyo), and the tensile strength was measured using a rheometer (Brookfield) by placing the patch between the tester grips, setting the grip separation speed to 500 ± 50 mm / min, and then measuring the maximum 10% elongation at break.

[0164] For adhesion, a patch with a width of 24±0.5 mm and a length of 100 mm was placed on one end of a stainless steel panel, pressed to about 30 mm using a 2040±45 g rubber roller, and the patch and panel were placed on the tester at 180°, pulled at a crosshead speed of 5±0.5 mm / s, and the load was measured, and the load at 12 mm was calculated and evaluated.

[0165] For absorption rate, the weight of the petri dish (W1) and the weight of the patch cut to 5 × 5 cm (W2) were measured. After placing the patch on the petri dish, preheated (37 ± 1 ℃) distilled water was added to the petri dish (40 times the sample weight), left at 37 ± 1 ℃ for 24 hours, and only the distilled water was removed from the petri dish and the weight was measured (W3). The specific calculation method is as follows:

[0166] [Mathematical Formula 1]

[0167] Absorption = (W3 - W1 - W2) / W2 x 100.

[0168] As shown in Table 4 below, the thickness of Patch 1 is 0.230 mm, which satisfies the target specification of 0.225 mm to 0.275 mm for being able to adhere thinly to the skin, and the tensile strength is 1496.90 gf / 12 mm, which satisfies the minimum target specification of 1000 gf / 12 mm for the patch not to be easily torn or broken, confirming excellent durability.

[0169] In addition, the adhesive force of Patch 1 was 543.00 gf / 12 mm, which satisfied the minimum target specification of 150 gf / 12 mm, confirming that it could be well attached without falling off from the skin.

[0170] The above patch 1 is a hydrocolloid patch that provides a moist environment, so the absorption rate was measured together. As a result, the absorption rate of patch 1 was 615.00% (24 hrs, g / cm 2 ) is the minimum target specification for absorbing pus from skin wounds, etc., which is 100% (24 hrs, g / cm). 2 ) was confirmed to exhibit high absorption rate.

[0171] Through the above results, it was confirmed that the patch 1 containing a mixture of salicylic acid and succinic acid exhibited excellent physical properties (thin thickness, high tensile strength, adhesiveness, and absorption rate) as an acne patch.

[0172] Patch 1 Thickness (mm) 0.230 Tensile strength (gf / 12 mm) 1496.90 Adhesion (gf / 12 mm) 543.00 Absorption rate (% (24 hrs, g / cm) 2 ))615.00

Claims

1. An antibacterial composition comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.

9.

2. An antibacterial composition according to claim 1, wherein the salicylic acid is contained in an amount of 0.3 to 0.5 wt% relative to the total weight of the antibacterial composition.

3. An antibacterial composition according to claim 1, wherein the antibacterial effect is achieved by inhibiting the growth, growth, or proliferation of acne-causing bacteria.

4. An antibacterial composition according to claim 3, wherein the acne-causing bacteria is at least one selected from the group consisting of Cutibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis.

5. An antibacterial composition according to claim 1, wherein the antibacterial composition alleviates acne symptoms.

6. An antibacterial composition according to claim 5, wherein the acne symptom is at least one selected from the group consisting of open comedones, closed comedones, papules, pustules, nodules, erythema, pseudocysts, and pustules.

7. A pharmaceutical composition for preventing or treating bacterial or fungal infectious skin diseases, comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.

9.

8. An antibacterial cosmetic composition comprising salicylic acid and succinic acid in a weight ratio of 1:1 to 1.

9.

9. An antibacterial skin external preparation containing salicylic acid and succinic acid in a weight ratio of 1:1 to 1.

9.

10. An antibacterial layer containing salicylic acid and succinic acid in a weight ratio of 1:1 to 1.9; and A patch having a multi-layer structure, which is disposed on the first surface of the antibacterial layer and includes a coating layer comprising thermoplastic polyurethane (TPU).

11. A patch according to claim 10, further comprising a release film layer comprising polyethylene terephthalate (PET) disposed on the second surface of the antibacterial layer.

12. A patch according to claim 10, wherein the antibacterial layer is a hydrogel.

13. A patch according to claim 12, wherein the hydrogel is a cross-linked hydrophilic polymer.

14. A patch according to claim 13, wherein the hydrophilic polymer is at least one selected from the group consisting of carboxymethyl cellulose, gelatin, collagen, pectin, ethyl cellulose, methylcellulose, polyether, hydroxypropylmethylcellulose, carmellose sodium, xanthan gum, and alginate.

15. A patch according to claim 10, wherein the antibacterial layer further comprises an adhesive.

16. In claim 15, the adhesive is hydrogenated styrene / butadiene copolymer, hydrogenated poly(C6-20 olefin), mineral oil, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, polyethylene glycol (PEG), poloxamer 407, rosin, glycol rosinate, glyceryl rosinate, pentaerythritol rosinate, hydrogenated A patch comprising at least one selected from the group consisting of hydrogenated rosinate, polyvinylpyrrolidone, and polyvinylpyrrolidone / vinyl acetate copolymer.

17. A patch according to claim 10, wherein the thickness of the patch is 0.225 to 0.275 mm.

18. A patch according to claim 10, wherein the tensile strength of the patch is 1400 to 1700 gf / 12 mm.

19. A patch according to claim 10, wherein the adhesive strength of the patch is 500 to 600 gf / 12 mm.

20. In claim 10, the absorption rate of the patch is 550 to 650% (24 hrs, g / cm 2 )in, patch.

Images